Document is current
Any future updates will be listed below
-
Authors
Guttman-Yassky, Emma https://orcid.org/0000-0002-9363-324X
Simpson, Eric https://orcid.org/0000-0003-0853-0252
Esfandiari, Ehsanollah
Mano, Hirotaka https://orcid.org/0000-0003-0103-7748
Bauer, Jillian https://orcid.org/0009-0006-1255-4918
Charuworn, Prista https://orcid.org/0000-0002-7284-5251
Kabashima, Kenji https://orcid.org/0000-0002-0773-0554
-
Funding
Funding for this research was provided by:
Amgen Inc.
- License Information
-
More Information
Article History
Received: 20 May 2025
Accepted: 8 July 2025
First Online: 6 September 2025
Declarations
:
: Emma Guttman-Yassky: is an employee of Mount Sinai. She has received research grants (paid to the institution) from Amgen, Anaptysbio, Aslan, Bristol Myers Squibb, Boehringer Ingelheim, Cara Therapeutics, Concert, GlaxoSmithKline, Incyte, Kyowa Kirin, Janssen, LEO Pharma, Pfizer, RAPT, Regeneron, Sanofi, and UCB; and is a consultant for AbbVie, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics Limited, Artax Biopharma, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Cara Therapeutics, Centrexion Therapeutics, Connect Biopharm, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Fairmount Funds Management, FL2022-001, Galderma, Gate Bio, Google Ventures, GlaxoSmithKline, Horizon Therapeutics, Incyte, Inmagene, Janssen Biotech, Japan Tobacco, Jasper Therapeutics, Kyowa Kirin, LEO Pharma, Merck, Nektar Therapeutics, Novartis Pharmaceuticals, Numab Therapeutics, OrbiMed Advisors, OTSUKA Pfizer, Pharmaxis, Pioneering Medicine VII, Proteologix US, RAPT, Regeneron, Ribon Therapeutics, Sanofi, SATO, Schrödinger, Sun Pharma Advanced Research Company, Teva Branded Pharmaceutical Products R&D, and UCB. Eric Simpson: reports personal fees from AbbVie, Amgen, Arcutis, Areteia Therapeutics, Bristol Myers Squibb, CorEvitas, Corvus, Dermira, Eli Lilly, Evelo Biosciences, FIDE, Forte Bio RX, Galderma, Gilead Sciences, GlaxoSmithKline, Impetus Healthcare, Incyte, Innovaderm Research, Janssen, Johnson & Johnson, Kyowa Kirin, LEO Pharma, Merck, MJH holding (4/29/2021), Numab Therapeutics AG, Pfizer, Physicians World, PRImE, Recludix Pharma, Regeneron, Roivant, Sanofi-Genzyme, Sitryx Therapeutics, Trevi Therapeutics, Valeant; grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Incyte, Lilly, Kymab, Kyowa Kirin, National Jewish Health, LEO Pharma, Pfizer, Regeneron, Sanofi, Target, and VeriSkin. Ehsanollah Esfandiari, Hirotaka Mano: employees of Kyowa Kirin International. Jillian Bauer, Prista Charuworn: current or former employees and stockholders in Amgen Inc. Kenji Kabashima: has received consulting fees, honoraria, grant support, and/or lecturing fees from Amgen, Kyowa Kirin, Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe, Ono Pharmaceutical, Procter & Gamble, Sanofi, Taiho, and Torii Pharmaceutical.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
